Notably, the presence of O-GlcNAc modifications on Tau and amyloid precursor protein (APP), both of which play crucial roles in the development of AD, has sparked interest in exploring the involvement of O-GlcNAc in the pathogenesis of AD. Here, MAPT is linked to Alzheimer disease.